POS0793-HPR OBSERVATIONAL STUDY IN REAL CLINICAL PRACTICE OF THE TREATMENT OF NON-INFECTIOUS UVEITIS

Background Uveitis is an ocular disease that a major cause of morbidity and blindness in the developed world. Although Immunosuppressive drugs biologic therapy have been shown to be effective their treatment there are no clear protocols for use. Objectives To describe characteristics patients with uveitis associated immunologic or idiopathic who require immunosuppressive response real clinical practice. Methods Observational, descriptive, longitudinal, retrospective study cohort diagnosed diseases attended multidisciplinary consultation between January 2011 February 2022. assess treatment, we evaluated change visual acuity vitritis presence macular edema. Results We included 356 (mean age at diagnosis 42.8 ± 15.8 years, 50% female). Of total, 157 (44%) had single flare 164 (46%) more than three. The involvement was bilateral 85 (24%) anterior (73%) (43%) were most frequent. Twelve percent required systemic corticosteroids 66 (18.5%) immunosuppressive/biological methotrexate being used (55%). Ten (15%) started biologics 34 (48%) them some point during disease, adalimumab used. Thirty-five (53%) needed drug due lack response. There differences different resolution improvement vision. Disappearance edema achieved all treated tocilizumab. Conclusion use immunosuppressive/biologics necessary high number non-infectious uveitis. In our series tocilizumab proved significantly Reference [1]Gómez-Gómez A, Loza E, Rosario MP, Espinosa G, de Morales JMGR, Herrera JM, et al. Efficacy safety immunomodulatory intermediate posterior uveitis, panuveitis edema: A systematic literature review. Seminars Arthritis Rheumatism. 2020;50(6):1299-306. Figure 1. Timeline treatments and/or administered least two treatments, according diagnosis. Shaded: resolved RAAU: recurrent acute AS: axial spondyloarthropathy MTX: Methotrexate. ADA: MFM: mycophenolate mofetil IFX: infliximab TCZ: SAR: sarilumab CYA: Cyclosporine. SSZ: sulfasalazine Acknowledgements: NIL. Disclosure Interests None Declared.